Alnylam Pharmaceuticals' Amortization of Deferred Charges rose 27.95% to $13.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $45.2 million, marking a year-over-year increase of 4.98%. This contributed to the annual value of $43.0 million for FY2023, which is 4.61% up from last year.
As of Q3 2024, Alnylam Pharmaceuticals' Amortization of Deferred Charges stood at $13.1 million, which was up 34.75% from $9.7 million recorded in Q2 2024.
Alnylam Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $13.1 million during Q3 2024, with a 5-year trough of $9.4 million in Q1 2020.
Over the past 3 years, Alnylam Pharmaceuticals' median Amortization of Deferred Charges value was $10.3 million (recorded in 2022), while the average stood at $10.8 million.
Per our database at Business Quant, Alnylam Pharmaceuticals' Amortization of Deferred Charges fell by 12.10% in 2022 and then rose by 27.95% in 2024.
Alnylam Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $10.5 million in 2020, then fell by 3.98% to $10.1 million in 2021, then climbed by 4.94% to $10.6 million in 2022, then declined by 0.78% to $10.5 million in 2023, then climbed by 27.95% to $13.1 million in 2024.
Its Amortization of Deferred Charges stands at $13.1 million for Q3 2024, versus $9.7 million for Q2 2024 and $12.0 million for Q1 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value